Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis
Name:
Targeting the activated....pdf
Size:
7.734Mb
Format:
PDF
Description:
Found with Open Access Button
Affiliation
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UKIssue Date
2024
Metadata
Show full item recordAbstract
Background Targeting of solid cancers with chimeric antigen receptor (CAR)-T cells is limited by the lack of suitable tumor-specific antigens and the immunosuppressive, desmoplastic tumor microenvironment that impedes CAR-T cell infiltration, activity and persistence. We hypothesized that targeting the endosialin (CD248) receptor, strongly expressed by tumor-associated pericytes and perivascular cancer-associated fibroblasts, would circumvent these challenges and offer an exciting antigen for CAR-T cell therapy due to the close proximity of target cells to the tumor vasculature, the limited endosialin expression in normal tissues and the lack of phenotype observed in endosialin knockout mice.Methods We generated endosialin-directed E3K CAR-T cells from three immunocompetent mouse strains, BALB/c, FVB/N and C57BL/6. E3K CAR-T cell composition (CD4+/CD8+ ratio), activity in vitro against endosialin+ and endosialin- cells, and expansion and activity in vivo in syngeneic tumor models as well as in tumor-naive healthy and wounded mice and tumor-bearing endosialin knockout mice was assessed.Results E3K CAR-T cells were active in vitro against both mouse and human endosialin+, but not endosialin-, cells. Adoptively transferred E3K CAR-T cells exhibited no activity in endosialin knockout mice, tumor-naive endosialin wildtype mice or in wound healing models, demonstrating an absence of off-target and on-target/off-tumor activity. By contrast, adoptive transfer of E3K CAR-T cells into BALB/c, FVB/N or C57BL/6 mice bearing syngeneic breast or lung cancer lines depleted target cells in the tumor stroma resulting in increased tumor necrosis, reduced tumor growth and a substantial impairment in metastatic outgrowth.Conclusions Together these data highlight endosialin as a viable antigen for CAR-T cell therapy and that targeting stromal cells closely associated with the tumor vasculature avoids CAR-T cells having to navigate the harsh immunosuppressive tumor microenvironment. Further, the ability of E3K CAR-T cells to recognize and target both mouse and human endosialin+ cells makes a humanized and optimized E3K CAR a promising candidate for clinical development applicable to a broad range of solid tumor types.Citation
Ash SL, Orha R, Mole H, Dinesh-Kumar M, Lee SP, Turrell FK, et al. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis. Journal for immunotherapy of cancer. 2024 FEB;12(2). PubMed PMID: WOS:001174461500004. English.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2023-008608PubMed ID
38413223Additional Links
https://dx.doi.org/10.1136/jitc-2023-008608Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2023-008608
Scopus Count
Collections
Related articles
- Endosialin-Expressing Pericytes Promote Metastatic Dissemination.
- Authors: Viski C, König C, Kijewska M, Mogler C, Isacke CM, Augustin HG
- Issue date: 2016 Sep 15
- Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
- Authors: Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W
- Issue date: 2024
- Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.
- Authors: Bagley RG, Honma N, Weber W, Boutin P, Rouleau C, Shankara S, Kataoka S, Ishida I, Roberts BL, Teicher BA
- Issue date: 2008 Nov
- Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8(+) T cell infiltration.
- Authors: Gan L, Lu T, Lu Y, Song H, Zhang J, Zhang K, Lu S, Wu X, Nie F, Di S, Han D, Yang F, Qin W, Wen W
- Issue date: 2024 Sep 10
- Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
- Authors: McKenna MK, Ozcan A, Brenner D, Watanabe N, Legendre M, Thomas DG, Ashwood C, Cummings RD, Bonifant C, Markovitz DM, Brenner MK
- Issue date: 2023 Jan